Evidence map›Paper›PMID 36506643›Full record

ArticleFrontiers in allergy2022

IL-33 induces NF-κB activation in ILC2 that can be suppressed by

Shubhanshi Trivedi, Daniel Labuz, Cassandra E Deering-Rice, Chu Un Kim, Hayden Christensen, Sam Aamodt, Tom Huecksteadt, Karl Sanders, Kristi J Warren

Open access · goldAbstract read
In one paragraph

Article in Frontiers in allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Review
  3. Regulating Neutrophilic Asthma with IL-33: Maybe We Shouldn't Block IL-33 after All?American journal of respiratory cell and molecular biology · 2025
    Article
  4. Review
  5. Serum 17Frontiers in immunology · 2025
    Article
  6. Review
  7. Article
  8. Progesterone amplifies allergic inflammation and airway pathology in association with higher lung ILC2 responses.American journal of physiology. Lung cellular and molecular physiology · 2024
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Shubhanshi TrivediDivision of Infectious Disease, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States.
Daniel LabuzDivision of Infectious Disease, Department of Internal Medicine, University of Utah, Salt Lake City, UT, United States.
Cassandra E Deering-RiceDepartment of Pharmacology and Toxicology, University of Utah College of Pharmacy, Salt Lake City, UT, United States.
Chu Un KimDivision of Pulmonary Medicine, Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, United States.
Hayden ChristensenDivision of Pulmonary Medicine, Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, United States.
Sam AamodtDivision of Pulmonary Medicine, Department of Internal Medicine, University of Utah Health, Salt Lake City, UT, United States.
Tom HuecksteadtGeorge E Wahlen Department of Veterans Affairs Medical Center, VA Salt Lake City Health Care System, Salt Lake City, UT, United States.
Karl SandersGeorge E Wahlen Department of Veterans Affairs Medical Center, VA Salt Lake City Health Care System, Salt Lake City, UT, United States.
Kristi J WarrenGeorge E Wahlen Department of Veterans Affairs Medical Center, VA Salt Lake City Health Care System, Salt Lake City, UT, United States.
University of Utah · USVA Salt Lake City Healthcare System · US

Funding

BLRD VA IK2 BX004219
6 · The paper itself

Abstract

Asthmatic women tend to develop severe airway disease in their reproductive years, and 30%-40% of asthmatic women have peri-menstrual worsening of asthma symptoms. This indicates that fluctuations in ovarian hormones are involved in advancement of asthmatic disease and exacerbation of symptoms. Group 2 innate lymphoid cells, or ILC2, are readily detected in allergic conditions, such as rhinosinusitis, in individuals that develop nasal polyps do to allergen exposures, and in allergic asthma. ILC2 are airway localized immune cells activated by IL-33, an innate cytokine that perpetuates allergic inflammation by driving the production of IL-5 and IL-13. We have previously shown that ILC2 are highly activated in naïve and ovalbumin (OVA) challenged, female BALB/c mice in comparison to male mice following stimulation with IL-33. Here, we investigated the effect of steady-state ovarian hormones on ILC2 and the NF-κB signaling pathway following OVA sensitization and challenge. We found that estrogen-treated ovariectomized mice (OVX-E2) that had been challenged with OVA had reduced IL-5 and IL-13 production by lung ILC2 as compared to lung ILC2 isolated from intact male and female sham-operated controls that had been treated with OVA. ILC2 were isolated from untreated animals and co-cultured

Indexed as

allergyasthmaestrogenILC2 - group 2 innate lymphoid cellinterleukin-13interleukin-33interleukin-5

Identifiers

PMID36506643
PMCPMC9732027
OpenAlexW4310045061

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.